Sign In
Buy ARCT
$5.76
-0.160 (-2.70%)
At Close: Jul 31, 2026
Arcturus Therapeutics: Two Catalysts, One Runway, And A Stock Priced For Failure
02:33pm, Thursday, 12'th Feb 2026
Arcturus Therapeutics now centers on ARCT-032 (cystic fibrosis) and ARCT-810 (OTC deficiency), with Covid assets as secondary cash support. ARCT is priced as a busted biotech with optionality; cash ru
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
01:29am, Thursday, 29'th Jan 2026
Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the thirteen research firms that are covering the com
Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
05:30pm, Thursday, 08'th Jan 2026
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the
Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Passes Below 200 Day Moving Average – Should You Sell?
03:32am, Wednesday, 03'rd Dec 2025
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT - Get Free Report) passed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $14.17 and traded as l
ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know
12:52pm, Monday, 01'st Dec 2025
Arcturus Therapeutics' stock slides 59%, primarily due to mixed interim results from the phase II study of its investigational inhaled cystic fibrosis therapy, ARCT-032.
Arcturus Therapeutics to Attend Upcoming Investor Conference
04:01pm, Monday, 24'th Nov 2025
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the
Brokerages Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Target Price at $36.00
02:34am, Tuesday, 18'th Nov 2025
Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the twelve ratings firms that are currently covering the co
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2025 Earnings Call Transcript
09:01pm, Monday, 10'th Nov 2025
Arcturus Therapeutics Holdings Inc. ( ARCT ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Neda Safarzadeh - Vice President and Head of IR/PR & Marketing Joseph Payne - Foun
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates
06:13pm, Monday, 10'th Nov 2025
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $1.25. This compares to a loss of $0.26 per share a year ago.
Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress
04:01pm, Monday, 10'th Nov 2025
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the
NEWTOWN, Pa. , Nov. 10, 2025 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Arcturus Therapeutics Holdings Inc. ("Arcturus") (NASD
Earnings Preview: Arcturus Therapeutics (ARCT) Q3 Earnings Expected to Decline
12:02am, Tuesday, 04'th Nov 2025
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025
04:01pm, Tuesday, 28'th Oct 2025
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcturus Therapeutics Holdings Inc. - ARCT
10:00am, Tuesday, 28'th Oct 2025
NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arcturus Therapeutics Holdings Inc. ("Arcturus" or the "Company") (NASDAQ: ARCT). Such inv
Brokerages Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Price Target at $50.57
03:00am, Friday, 24'th Oct 2025
Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eleven brokerages that are currently covering the compa
